Mano Michael 4

What Happened

• Mano Michael, EVP, Chief Legal Officer & Secretary of Karyopharm Therapeutics (KPTI), had 700 performance-based restricted stock units (PSUs) certified as earned and vested on May 13, 2026; those PSUs convert into 700 shares (recorded as an award at $0.00). Following the vesting, 266 shares were sold in a broker-assisted sale on May 14, 2026 for $9.50 per share, generating $2,527 to satisfy withholding tax obligations. The net effect is an increase of 434 shares held by the reporting person (700 acquired less 266 sold).

Key Details

• Award vested: 700 PSUs converted to 700 shares on May 13, 2026 (reported acquisition at $0.00) — footnote F1.
• Sale to cover taxes: 266 shares sold on May 14, 2026 at $9.50/share for $2,527; sale executed under a durable automatic sale instruction plan (broker-assisted) adopted May 16, 2022 — footnote F2; sale was non‑discretionary and done to satisfy withholding.
• Filing: Form 4 filed May 15, 2026 covering transactions through May 13, 2026 (timely filing).
• Shares owned after transaction: the disclosure shows a net increase of 434 shares from these events; total outstanding holdings after the transaction were not provided in the excerpt.

Context

• PSUs are performance-based restricted stock units — these were earned because a clinical trial enrollment milestone was certified by the company’s Compensation Committee; each earned PSU converts to one share upon vesting.
• The sale was solely to meet tax withholding related to the vesting and was executed under an automatic plan, not an active discretionary sale by the insider. Such tax-withholding sales are common and do not necessarily signal a change in the insider’s view of the company.